Somewhat Critical News Coverage Somewhat Unlikely to Impact Ariad Pharmaceuticals (ARIA) Stock Price
News headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have trended somewhat negative recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave news coverage about the pharmaceutical company an impact score of 45.6894302530979 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Gastrointestinal Stromal Tumor (GIST) Drug Market – Global Market Research Report Covering Ariad Pharmaceuticals … – MilTech (military-technologies.net)
- Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17 (finance.yahoo.com)
- Future of the Global Gastrointestinal Stromal Tumor (GIST) Drug Market – Growth, Latest Trend & Forecast 2022 – Newsient (blog) (newsient.com)
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) -in-Depth Analysis of Therapeutic Development of key … – Medgadget (blog) (medgadget.com)
- Leukemia Therapeutic Market: Global Forecast over 2021 … – MilTech (military-technologies.net)
Ariad Pharmaceuticals (NASDAQ:ARIA) remained flat at $$23.99 during trading hours on Friday. The company has a debt-to-equity ratio of -11.28, a quick ratio of 3.15 and a current ratio of 3.17.
Ariad Pharmaceuticals Company Profile
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.